Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
VELCADE based regimens are cost-effective for payers and patients, finds study

VELCADE based regimens are cost-effective for payers and patients, finds study

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Tibotec Therapeutics'  INTELENCE granted FDA traditional approval

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm presents LE-DT Phase I data at the AACR conference

University of Michigan to develop novel therapy for neuropathic pain

University of Michigan to develop novel therapy for neuropathic pain

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

HealthCore study shows Metanx tablets reduces health plan costs

HealthCore study shows Metanx tablets reduces health plan costs

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors at risk of effective treatment

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Preventing nerve cell death in diabetics

Preventing nerve cell death in diabetics

Diabetic nerve pain: Most bothersome complication of diabetes

Diabetic nerve pain: Most bothersome complication of diabetes

New electronic medical device for treating leg pain

New electronic medical device for treating leg pain

Rebuilder Medical Technologies is in concluding stages of finalizing a national contract to provide billing services for all physicians

Rebuilder Medical Technologies is in concluding stages of finalizing a national contract to provide billing services for all physicians

ReBuilder Medical Technologies reports 100% increase in second-quarter 2009 profits over first-quarter

ReBuilder Medical Technologies reports 100% increase in second-quarter 2009 profits over first-quarter

Significant drop in prevalence of rheumatoid vasculitis between 2000 and 2001

Significant drop in prevalence of rheumatoid vasculitis between 2000 and 2001

New online educational forum for medical professionals from HMP Communications

New online educational forum for medical professionals from HMP Communications

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.